Compodium International (COMPDM) Q3 2026 earnings summary

Executive summary

• ARR rose 8.7% YoY to SEK 44.9m, while Q3 revenue declined 3.4% to SEK 10.4m; EBITDA remained positive at SEK 2.0m.

• A prehospital-care deployment and stronger existing-customer retention supported recurring revenue growth; focus remains on converting ARR into sustained revenue growth.

Financial highlights

• Q3 revenue was SEK 10.4m vs SEK 10.8m YoY; Jan-Sep revenue was SEK 32.1m vs SEK 33.3m.

• Q3 gross profit was SEK 8.8m vs SEK 9.5m; EBITDA was SEK 2.0m vs SEK 3.1m, and net loss was SEK 2.4m vs SEK 2.7m.

• Jan-Sep EBITDA was SEK 7.3m vs SEK 7.6m; EBIT was -SEK 8.8m vs -SEK 10.6m, and net loss was SEK 7.9m vs SEK 9.7m.

• Q3 operating cash flow was -SEK 1.7m vs SEK 0.4m; total cash flow was -SEK 3.4m vs -SEK 0.2m, with cash of SEK 6.2m at quarter-end.

Outlook and guidance

• Q4 priorities are developing opportunities from the new packaging and prehospital-care deployment, expanding existing accounts, and winning new customers.

• ARR growth is expected to flow through to revenue progressively; continued cost discipline and targeted sales investment underpin the aim of sustainable growth and long-term profitability.